Agios Pharmaceuticals (AGIO) vs. The Competition Financial Analysis
Agios Pharmaceuticals (NASDAQ: AGIO) is one of 291 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Agios Pharmaceuticals to similar businesses based on the strength of its earnings, dividends, analyst recommendations, valuation, risk, institutional ownership and profitability.
Volatility & Risk
Agios Pharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ peers have a beta of 0.27, meaning that their average share price is 73% less volatile than the S&P 500.
82.7% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Agios Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Agios Pharmaceuticals Competitors||1176||3523||12063||248||2.67|
Agios Pharmaceuticals currently has a consensus target price of $77.00, indicating a potential downside of 4.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.86%. Given Agios Pharmaceuticals’ peers higher probable upside, analysts plainly believe Agios Pharmaceuticals has less favorable growth aspects than its peers.
This table compares Agios Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Agios Pharmaceuticals Competitors||-5,345.53%||-158.67%||-35.84%|
Valuation & Earnings
This table compares Agios Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agios Pharmaceuticals||$69.89 million||-$198.47 million||-12.81|
|Agios Pharmaceuticals Competitors||$290.27 million||$35.99 million||68.50|
Agios Pharmaceuticals’ peers have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.